MiMedx Group, Inc. (NASDAQ:MDXG) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,794,358 shares of the company’s stock after purchasing an additional 44,254 shares during the period. Geode Capital Management LLC owned about 1.90% of MiMedx Group worth $16,518,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MDXG. Isthmus Partners LLC boosted its holdings in MiMedx Group by 30.4% in the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares during the period. Blue Trust Inc. acquired a new stake in MiMedx Group in the 3rd quarter valued at about $30,000. Point72 Asset Management L.P. purchased a new position in shares of MiMedx Group in the 2nd quarter valued at about $40,000. Point72 DIFC Ltd grew its position in shares of MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of MiMedx Group during the third quarter worth approximately $64,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Stock Performance

NASDAQ MDXG opened at $9.42 on Monday. The company has a fifty day moving average of $8.35 and a two-hundred day moving average of $7.17. The company has a market capitalization of $1.38 billion, a PE ratio of 17.13 and a beta of 1.98. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, MiMedx Group currently has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.